

RESEARCH ARTICLE

Open Access



A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema

Ye He¹, Xin-jun Ren^{1†}, Bo-jie Hu^{1†}, Wai-Ching Lam² and Xiao-rong Li^{1*}

Abstract

Background: This meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME).

Methods: The PubMed, Embase, clinicaltrials.gov website and Cochrane Library databases were comprehensively searched for studies comparing DEX implant with anti-VEGF in patients with DME. Best-corrected visual acuity (BCVA), central subfield thickness (CST) and adverse events were extracted from the final eligible studies. Review Manager (RevMan) 5.3 for Mac was used to analyze the data and GRADE profiler were used to access the quality of outcomes.

Results: Based on four randomized clinical trials assessing a total of 521 eyes, the DEX implant can achieve visual acuity improvement for DME at rates similar to those achieved via anti-VEGF treatment (mean difference [MD] = -0.43, $P = 0.35$), with superior anatomic outcomes at 6 months (MD = -86.71 μm , $P = 0.02$), while requiring fewer injections, in comparison to anti-VEGF treatment. Although the mean reduction in CST did not showed significant difference at 12 months (MD = -33.77 μm , $P = 0.21$), the significant in BCVA from baseline to 12 months supported the anti-VEGF treatment (MD = -3.26, $P < 0.00001$). No statistically significant differences in terms of the serious adverse events. However, use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment.

Conclusions: Compared with anti-VEGF, DEX implant improved anatomical outcomes significantly. However, this did not translate to improved visual acuity, which may be due to the progression of cataract. Therefore, the DEX implant may be recommended as a first choice for select cases, such as for pseudophakic eyes, anti-VEGF-resistant eyes, or patients reluctant to receive intravitreal injections frequently.

Keywords: Diabetic macular edema, Ozurdex, Dexamethasone implant, Anti-VEGF, Meta-analysis

Background

Macular edema (ME) is not an independent disease, but a common phenomenon in various retinal diseases in which fluid and protein accumulate in the extracellular space within the retina [1, 2]. Diabetic macular edema (DME) is macular thickening secondary to diabetic retinopathy

(DR) that may be present in any of the stages of this disease, although it manifests more commonly in the non-proliferative diabetic retinopathy stage. In patients with DR, aged 20 to 79 years, the global prevalence for DME is 6.8% [3]. The prevalence of DME is reported to be related to the duration of the diabetes [4, 5]. DME is the foremost cause of central vision loss, and even blindness, and has a great influence on life quality of patients. Thus, reduction of ME may be associated with improved vision.

However, the treatment of DME remains controversial among vitreoretinal specialists. In addition to glycemic

* Correspondence: xiaorli@163.com

†Equal contributors

¹Department of Retina, Tianjin Medical University Eye Hospital, 251 Fukang Road, Tianjin 300384, China

Full list of author information is available at the end of the article



control, a variety of treatment alternatives exist for patients presenting with DME, including focal or grid photocoagulation, which has been the standard therapy since the 1970s, and more recently, intravitreal injection (anti-VEGF or corticosteroids) has been applied to DME, and vitrectomy in patients with DME with vitreomacular traction. As understanding of the pathophysiology of DME has improved, focal or grid photocoagulation is no longer the first choice for the treatment of DME. Treatment now targets the causal factor specifically, VEGF. To date, anti-VEGF drugs, including aflibercept, ranibizumab, and bevacizumab, have been proven in many clinical trials with efficacy for DME. The RESOLVE [6], RISE/RIDE [7, 8], and READ-2 [9] studies have all shown that ranibizumab is a good choice for the treatment of DME. The BOLT [10] randomized trial showed that bevacizumab is superior to laser monotherapy for persistent center-involving clinically significant macular edema.

Anti-VEGF drugs is still the first-line for treating DME, but also may impose a significant burden for patients who either do not have good respond to anti-VEGF or have recurrent ME, require frequent anti-VEGF injections [11]. Indeed, a study by the Diabetic Retinopathy Clinical Research Network (DRCR. Net), Protocol I revealed that more than 40% of ranibizumab-treated eyes still had CST \geq 250 μ m at 2 years post-treatment. The limited visual gains or resolution of DME in those naive patients are believed to be related to the pathophysiology of DME. Although the contribution of VEGF to the development of DME is indisputable, the role of other non-VEGF pathways has also been considered. Many studies have demonstrated that the inflammation is involved in the DR progression. With the increased recognition of the role of inflammation in the development of DME, sustained-release implants of steroids have shown good anatomical benefit and have also, to some extent, reduced the number of intravitreal injections that is needed in most cases.

Dexamethasone, it has the highest relative clinical efficacy of any corticosteroid applied to ophthalmological practice, and exerts its multiple-effects via its influence on multiple signal transduction pathways. The 0.7 mg intravitreal DEX implant is a biodegradable solid polymer drug-delivery system (Ozurdex[®], Allergan, Inc.), which uses the following characteristic mode of drug release by diffusion, in a biphasic fashion: an initial high-concentration phase and a second low-concentration phase, which facilitates continued efficacy of the treatment for up to 6 months [12]. The U.S. Food & Drug Administration (FDA) first approved the Ozurdex for retinal vein occlusion-induced ME treatment in 2009. It was then approved for non-infectious uveitis treatment. In 2014, the FDA and most European countries approved Ozurdex for the treatment of DME, based on results of the MEAD study [13]. Studies of treatment of DME have demonstrated that Ozurdex may be an alternative

treatment for patients who do not have good respond to serial anti-VEGF injections or in recalcitrant cases [14–19]. In addition, Ozurdex may be considered as primary treatment for DME [20].

To date, no systematic review has discussed the therapeutic effect and safety of intravitreal anti-VEGF versus DEX implant in DME. We performed a systematic review and meta-analysis to quantify the effect of these two treatments on BCVA and CST in DME. Additionally, we report the adverse events described with these therapies.

Methods

Search strategy

The study was conducted in accordance with Cochrane Handbook for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Additional file 1) [21]. The following databases were screened: including PubMed, Embase, clinicaltrials.gov, and the Cochrane Library, up to August 2017 (Additional file 2, Table 1). Keywords, including macular edema, dexamethasone intravitreal implant, dexamethasone, anti-VEGF, and Ozurdex were used to maximise the search accuracy. The literature selections are shown in the PRISMA flow diagram in Fig. 1.

Inclusion and exclusion criteria


Studies were regarded eligible if they accord with the following criterias: (1) the study population included patients with DME; (2) the DEX implant (Ozurdex) was included as an intervention; (3) there was a comparison between the DEX implant (Ozurdex[®]) and anti-VEGF. Through our analysis of the studies, we determined the following primary outcomes. First, the mean BCVA and mean improvement from baseline in BCVA [time points: baseline, 6 months, and 12 months]. BCVA was obtained using the Early Treatment Diabetic Retinopathy Study (ETDRS). Second, the mean CST and mean change from baseline in CST or foveal thickness, and central macular thickness (CMT) was demonstrated on optical coherence tomography (OCT) [time points: baseline, 6 months, and 12 months]. Additional outcomes collected included the following: 1) total number of serious adverse events (SAEs) at the end of each study; 2) elevation of intraocular pressure (IOP>21 mmHg, required glaucoma agents for IOP control, or IOP elevation by at least 5 mmHg from baseline at any follow-up visit; 3) the number of cataracts; 4) the mean number of intravitreal injections; and 5) the study design should be randomized controlled trials (RCTs).

We designed the study to have no limitations on dose. Patients taking bevacizumab and ranibizumab were placed in the anti-VEGF group. The two authors, Ye He and Bojie Hu assessed all eligible studies independently. A consensus was reached if there were any cases of disagreement. The exclusion criteria included studies with insufficient data, non-RCTs, case reports, review articles.

Table 1 Summary of the characteristics of the included studies

Study	Place	Conditions	Participants numbers	Interventions details	Total number of treatments	Age (years)	Female sex, no. (%)	BCVA at baseline	CST/CMT (μ m) at baseline	Follow-up duration (months)
Gillies et al. 2014 < The BEVORDEX Study> [23]	Australia	DR	DEX: 46 IVB: 42	DEX: 0.7 mg every 16 weeks + PRN IVB: 0.5 mg every 4 weeks + PRN	DEX: 2.7 IVB: 8.6	DEX: 61.4 \pm 9.0 IVB: 62.2 \pm 10.5 (<i>P</i> = 0.71)	DEX: 16 (35%) IVB: 16 (38%) (<i>P</i> = 0.83)	DEX: 55.5 \pm 12.5 IVB: 56.3 \pm 11.9 (<i>P</i> = 0.75)	DEX: 474.3 \pm 95.9 IVB: 503 \pm 140.9 (<i>P</i> = 0.38)	12
Allergan 2015 [27]	Multiple countries: Belgium, Denmark, France, Germany, Israel, Italy, Netherlands, Portugal, South Africa, Spain, United Kingdom, United States	DR	DEX: 181 IVR: 182	DEX: 0.7 mg on Day 1, Month 5, and Month 10 IVR: 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression	NA	NA	DEX: 69 (38%) IVR: 66 (36%)	DEX: 60.2 \pm 9.74 IVR: 60.4 \pm 9.34	DEX: 465.1 \pm 136.09 IVR: 471.2 \pm 139.51	12
Shah et al. 2016 [24]	Indiana, United States	DR	DEX: 27 IVB: 23	DEX: 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections IVB: 1.25 mg given monthly during a 6 month period	DEX: 2.7 \pm 0.5 IVB: 7.0 \pm 0.2 (<i>P</i> < 0.001)	DEX: 65 \pm 11 IVB: 61 \pm 9 (<i>P</i> = 0.209)	DEX: 15 (56%) IVB: 10 (44%) (<i>P</i> = 0.571)	DEX: 59 \pm 12 IVB: 59 \pm 13 (<i>P</i> = 0.770)	DEX: 458 \pm 100 IVB: 485 \pm 122 (<i>P</i> = 0.508)	7
Gallemore et al. 2017 [26]	California, United States	DR	DEX: 10 IVB: 10	DEX: Ozurdex, 0.7 mg given at initial visit and at month 4 (visit 5) IVB: 1.25 mg given at initial visit and Q1 month for a total of 5 treatments	NA	DEX: 63.9 \pm 1.8 IVB: 61.2 \pm 2.9	DEX: 5 (50%) IVB: 3 (30%)	DEX: 67.8 \pm 3.8 IVB: 71.9 \pm 2.9	DEX: 385.9 \pm 43.0 IVB: 341.5 \pm 11.3	6

NA not available, PRN pro re nata



Data extraction and risk of bias assessment

The relevant data from the articles were extracted by two reviewers (Ye He and Bo-jie Hu) independently, using a standard data extraction form. The extracted data included the first author(s) or the information provider, publishing date, study design, sample size, geographical location of the research, interventions details, age, sex, outcomes and follow-up periods. We emailed the corresponding authors of the studies for which we had unanswered questions to ensure completeness of our study, and to acquire incomplete and missing data. Data are showed in the format: mean ± standard deviation (SD). We used the formula that $SD = SE \cdot \sqrt{N}$ to calculate SD if the data was reported as standard error (SE). Afterwards, we used Get Data software to estimate the mean and the SD from the reported graph. The Cochrane Collaboration’s tool was applied to assess the risk of bias in each study based on the Cochrane Handbook.

Statistical analysis

RevMan 5.3 was applied to integration collected data statistics and analysis. The mean difference (MD) and risk ratio (RR) were used to assess continuous variable outcomes and dichotomous outcomes with a 95% confidence interval

[CI], respectively. The heterogeneity of studies was accessed using the chi-square test based on the values of P and I^2 . The random-effects model was applied for the meta-analysis. I^2 results between 50 and 100% represented substantial heterogeneity. P values < 0.05 were considered statistically significant.

Quality of the evidence

The evidence quality of all included outcomes was evaluated based on the GRADE system [22]. Initially, RCTs were regarded as high-quality evidence for the estimation of study effects. Factors such as risk of bias, imprecision and inconsistency of results etc., all of which can result in rating down the quality of evidence for specific outcomes, reduced the level of confidence in estimating the study effects. The GRADE evidence was divided into the four categories (High, Moderate, Low and Very low-quality evidence).

Results

Search results

A total of 176 potential records up to August 2017 were identified with the electronic-based search (PubMed = 83, Embase = 52, clinicaltrials.gov=38, and the Cochrane

Library = 3). After eliminating 50 duplicates, a total of 126 potentially eligible studies were retrieved. After reading the title and abstract, 116 of these studies were excluded. We further excluded three studies after reading the full text due to ineligible for criteria. Among the 7 studies included in the qualitative synthesis, two clinical trials (ClinicalTrials.gov identifier: NCT01298076; NCT02036424) were duplicates, because the data had already been published. Among these published articles [23–25], the outcome of one article did not meet the inclusion criteria [25]. After looking through all eligible studies, four studies comprising 521 study eyes were used in our meta-analysis (Fig. 1) [23, 24, 26, 27].


All of included studies were RCTs and the characteristics of these studies are summarized in Table 1. The sample size of the four studies ranged from 20 to 363. Two studies were published in 2014 and 2016. Two studies reported their

results online and verified the results in January 2015 and April 2017, respectively. In all included studies, the dose of the DEX implant was the same. However, in the study by Shah et al., dexamethasone (0.7 mg) was given every 3 months instead of every 4 months as in the other included studies. Among them, Gillies et al., Shah et al., and Gallemore et al. performed intravitreal bevacizumab (IVB) injection, while Allergan study used intravitreal ranibizumab (IVR) injection. The risk of bias assessment and the results of the GRADE evidence are presented in Fig. 2 and Additional file 2: Table S2, respectively.

Meta-analysis results

Mean BCVA at 6 months

Data from three studies assessing 157 eyes (82 eyes with DEX treatment, 75 eyes with anti-VEGF treatment) reported the BCVA at 6 months. No difference in the treatment effect



on BCVA at 6 months between the two treatment arms; the MD in visual acuity of the three trials was -0.43 (95% CI: -1.32 to 0.47 , $P = 0.35$, Fig. 3). No statistical heterogeneity was found ($\chi^2 = 0.26$, $P = 0.88$, $I^2 = 0\%$).

Mean change in BCVA at 6 months and 12 months

At 6 months, data from three studies assessing 157 eyes reported the an improvement in BCVA from baseline. Because the clinical effect in 6 months was similar to that in 7 months, we used the data from month 7 to represent month 6 in the study by Shah et al. [24]. The DEX group reported a similar mean change in BCVA from baseline compared with the anti-VEGF group (MD = 0.32 ; 95% CI, -2.54 to 3.17 ; $P = 0.83$; Fig. 4), and no heterogeneity was found ($P = 0.99$, $I^2 = 0\%$). A meta-analysis at 12 months was conducted using two studies of 451 eyes to assess the improvement in BCVA from baseline. Statistically significant differences were discovered between the DEX implant and anti-VEGF treatment groups, in favor of the anti-VEGF group (MD = -3.26 , 95% CI: -4.66 to -1.86 , $P < 0.00001$; Fig. 4) and no heterogeneity was found ($P = 0.99$, $I^2 = 0\%$).

Mean CST at 6 months

Three studies of 157 eyes included data on CST at 6 months after the initial treatment. Meta-analysis demonstrated that all studies except that by Gallemore et al. [26] showed a marked reduction in CST from baseline in the DEX group. The MD for all studies at 6 months was statistically significant (MD = -86.71 μm , 95% CI: -161.61 to -11.82 , $P = 0.02$) in favor of DEX treatment over anti-VEGF treatment, and showed high heterogeneity ($P < 0.00001$, $I^2 = 95\%$; Fig. 5).

Mean change in CST at 6 months and 12 months

Data from three studies assessing 157 eyes reported the mean change from baseline to 6 months in terms of the reduction of CST was significantly greater in the DEX groups (MD = -88.74 , 95% CI: -122.85 to -54.63 , $P < 0.00001$, Fig. 6). However, this superiority was no longer observed at 12 months. Data from two studies assessing 417 eyes at 12 months, with a combined mean difference in CST of -33.77 μm , did not show statistically significant differences (95% CI: -86.72 to -19.18 , $P = 0.21$), and showed a large amount of heterogeneity between the two studies ($P = 0.08$, $I^2 = 68\%$, Fig. 6).

Total serious adverse events

All four studies reported complications during the follow-up period, such as increased IOP, cataract, and vitreous hemorrhage. In these studies, the study by Gallemore et al. reported no serious adverse events during the follow-up period. The total SAEs reported by the three studies are presented in the forest plot (Fig. 7). Analysis of the available data demonstrated a lower incidence of serious adverse events in the DEX arm (RR = 0.89), with no heterogeneity ($P = 0.44$, $I^2 = 0\%$), however the differences were not statistically significant (95% CI: 0.63 to 1.26 ; $P = 0.51$).

Elevation of IOP

All cases demonstrated increased IOP after injection of DEX/anti-VEGF; this was mostly controllable by medication or surgery. Low heterogeneity was detected between studies ($I^2 = 43\%$, $P = 0.15$, Fig. 8). Analysis using a random-effects model demonstrated a statistically significant difference between DEX and anti-VEGF treatment (RR = 4.14 ; 95% CI: 1.89 to 8.65 ; $P = 0.0002$).

Adverse events: cataract

Three studies involving 501 eyes reported post-operative cataract. Statistically significant difference was founded between the DEX and anti-VEGF groups (RR = 2.68 , 95% CI: 1.54 to 4.68 , $P = 0.0005$), without heterogeneity ($P = 0.44$, $I^2 = 0\%$, Fig. 9).

Mean number of intravitreal injections

In the study by Shah et al. [24], more injections were required in the IVB group (7.0 ± 0.2) compared to the DEX group ($P = 0.001$) over a follow-up period. Similarly, no statistically significant difference in BCVA according to Gillies et al., but a lower treatment frequency was required for the DEX implant (mean number: 2.7), which was an obvious advantage over IVB treatment (mean number: 8.6) [23].

Discussion

In our study, we evaluated four RCTs to evaluate the efficacies of DEX implants and anti-VEGF in the treatment of DME. We found that both DEX implant and anti-VEGF could achieve significant functional and anatomical improvement during early treatment. We did not find statistically significant differences in terms of BCVA and with no statistical





Fig. 3 A forest plot diagram showing the mean BCVA and the associated 95% CI, comparing DEX with Anti-VEGF treatment at 6 months





heterogeneity between these two treatment arms at 6 months. However, the anti-VEGF group revealed significant improvement in BCVA at 12 months, compared to the DEX implant group, and without statistical heterogeneity. These findings are in line with the Protocol I in [DRCR.net](#), whereby the ranibizumab group had better visual acuity than the triamcinolone group.

Even with good treatment effects, repeated injections carry increased risks, such as infectious endophthalmitis, intraocular inflammation, and even stroke or myocardial infarction [28]. Therefore, anti-VEGF treatment may not be a good therapy for all patients. DME has been shown to be a complex multifactorial disease; in addition to VEGF, inflammation may be another pathophysiological feature of these treatment-naive patients. Diabetics are found to have high concentrations of pro-inflammatory cytokines, such as interleukin 6 (IL-6), IL-1 β , tumor necrosis factor α (TNF α), and intracellular adhesion molecule (ICAM)-1. All of these cytokines induce retina with persistent chronic inflammation, which leads to leukostasis, increased vascular permeability and dysfunction of the blood-retinal barrier (BRB) [29, 30]. Additionally, according to an investigation by Jonas et al. [31], DME was shown to be related to elevated cytokines in the aqueous humor or vitreous, such as ICAM-1, IL-6, transforming growth factor beta (TGF- β) and monocyte chemotactic protein 1 (MCP-1). Among the cytokines,

ICAM-1 is closely related with diabetes characteristics. Thus, treatment principally aims to block the effect of these two pathogenic pathways. Corticosteroids have anti-inflammatory, anti-permeability, and angiostatic effects when treating DME [32]. Thus, DEX implant could be a better alternative for DME.

Our analysis demonstrated that DEX implant treatment could significantly reduce CST at 6 months, compared to anti-VEGF treatment. Unfortunately, this effect can not last until 12 months. This can be explained by the characteristics of the DEX implant. There are two phases in the DEX implant treatment. Higher concentrations of DEX are found in the initial phase, followed by lower concentrations in the final phase. The drug reaches its peak efficacy less than two months after administration. Afterwards, the drug continues to provide treatment, but, at lower levels in months 2–6 [12]. Regarding heterogeneity, we could not perform a subgroup analysis to interpret the potential source of heterogeneity, due to the limited studies. We suspect that, at 6 months, the heterogeneity mainly derives from the small sample size of the study by Gallemore et al. Moreover, the results of CST may be affected by other factors, including initial retinal thickness, the dosage of bevacizumab, and previous treatment (laser or anti-VEGF). The mean change in CST at 12 months showed heterogeneity mainly caused by the






type of anti-VEGF drugs used. In the Allergan 2015 study [27], patients received 0.5 mg ranibizumab. However, in the BEVORDEX study [23], 0.5 mg bevacizumab was given to the patients. It has been reported that ranibizumab and bevacizumab do not differ in terms of functional outcomes, but that ranibizumab was more effective in terms of CST reduction [33]. Factors such as race, dosage, age, and baseline states may have attributed to heterogeneity. To some extent, these factors were unavoidable. In terms of CST, at 6 months, Ozurdex showed superior reduction in CST, which indicates that patients with DME can achieve superior anatomical outcomes with fewer injections. Similar to our results, the results from the MEAD study evaluating the DEX implant showed that a mean number of 4.1 DEX treatments were administered after 3 years of follow-up. Compared to the sham group, the DEX group acquired a CST reduction of 112 μm, nearly three times than the sham group (42 μm).

Notably, the improved anatomical outcomes in our data did not translate to improved visual acuity outcomes. Results from other clinical trials were consistent with the four studies included here. In the CHROME study [34], significant reduction in retinal thickness were occurred in the Ozurdex group: 190.9 ± 23.5 μm for DME (P < 0.0001). The greatest mean improvements in

BCVA in terms of number of lines of vision observed in the eyes with DME (0.7 ± 0.5; P > 0.05). Similarly, compared to monthly IVB monotherapy (-30 μm), the combination therapy with DEX and bevacizumab led to a significantly greater change of CST (-45 μm) in the study by Maturi et al.; nevertheless, visual acuity improvement was not statistically significant [35]. The limited visual gains in these patients may have been related to the duration of macular edema, neural damage, retinal pigment epithelium changes, and subretinal fibrosis caused by chronic macular edema prior to treatment, as well as the result of structural damage from repeated macular laser therapy, and the natural course of DR [7].

Additionally, we suspect that it may be due to DEX-induced progression of cataract, based on previous studies. In the DRCR Protocol I, when controlling for cataract formation, in pseudophakic eyes, the group that received triamcinolone observed similar BCVA results to the ranibizumab group. Similar to this study, the CHROME study also showed that the pseudophakic eyes with DME acquired a average gain of 1.4 ± 0.5 lines, but a average loss of 0.6 ± 0.6 lines was shown in phakic eyes [34]. These results are also in agreement with those of the BEVORDEX study, which found exhibited no significant effect for pseudophakic eyes. Compared to 10.4






Fig. 8 A forest plot diagram showing the elevation of IOP

letters in the dexamethasone group, the mean change in BCVA for the bevacizumab group was 7.7 letters ($P = 0.47$). Moreover, visual acuity may be affected by post-operative complications, such as Irvine–Gass syndrome or cataract secondary to pars plana vitrectomy prior to DEX or anti-VEGF treatment.

In addition to having different efficacies for treating DME, DEX implants and anti-VEGF injection are associated with varying degrees of increased risk of systemic and/or local complications over the period of treatment. The systemic adverse event rate has been reported to be higher with anti-VEGF treatment in some clinical trials [36]. In the study by Avery et al., the increased potentially cerebrovascular accidents may be link to anti-VEGF treatment, especially after two years therapy [37]. Similar to previous studies, our data demonstrated that a lower incidence of SAEs in the DEX implant group, but this was not statistically significantly different between the DEX and anti-VEGF group. These results suggest that we should be cautious in using anti-VEGF in patients with myocardial infarction and stroke [38]. The deterioration of hypertension was the most frequent systemic adverse event encountered in the BEVORDEX study. Other adverse events, such as cardiac disorders, also occurred in the studies included in this meta-analysis, except in the study by Gallemore et al. High IOP and secondary cataract are the most common ocular adverse events of DEX implants. Our meta-analysis agrees with these findings, which demonstrated a statistically significant difference between the two groups in

terms of increased IOP and cataract. The groups receiving DEX had a higher risk of a rise in IOP and cataract progression than the anti-VEGF groups for DME. This suggests that the ophthalmologist should take care when using DEX implants in patients with high IOP or in young patients with a clear lens.

The relative benefits and costs should also be considered when applying therapies. In terms of cost-effectiveness, intravitreal corticosteroid injections are relatively cheaper than anti-VEGF therapies, although this is not true for ranibizumab. One study calculated the amount of money (USD) saved per line of visual acuity improvement for each of the various therapies as follows: DEX implant—\$5666, bevacizumab—\$1329–\$2246, and ranibizumab—\$11,372–\$11,609. In addition, the dollars per quality-adjusted life year for these therapies were as follows: DEX implant—\$9446, bevacizumab—\$2013–\$4260, and ranibizumab—\$19,251–\$23,119 [39].

Currently, dexamethasone delivery systems and anti-VEGF therapies have a positive effect on the course of DME. However, these two different types of drugs have different pharmacological properties and side-effect characteristics. Given the results of clinical trials and the pathophysiology of DME, Ozurdex is considered to be the preferred treatment for patients who have chronic DME and are anti-VEGF-resistant, as an alternative to switching between anti-VEGF drugs [40, 41]. Ozurdex may be recommended as a first choice for the following cases: 1. pseudophakic eyes, or patients who are under consideration for cataract surgery in the near future; 2.




Fig. 9 A forest plot diagram showing the adverse events: cataract

patients who are anti-VEGF-resistant [42]; 3. patients who have a history of cardiovascular and cerebrovascular diseases [42]; 4. post-vitreotomy patients [18]; 5. patients without a high IOP risk at baseline; 6. patients who are reluctant to receive frequent injections. In all cases, the IOP should to be monitored frequently. Reinjection of Ozurdex can be considered after approximately 3–6 months if remains evidence of impaired vision and residual ME.

Our study was limited by the following factors: (1) We only included four studies assessing a total of 521 eyes. (2) The clinical trials duration was quite short in some of the that were included, and thus we may have underestimated the drug-induced adverse events. (3) Heterogeneity was inevitable due to the different regimens of anti-VEGF therapies used. Previous studies indicated that the efficacy of aflibercept, ranibizumab or bevacizumab for DME was different but the relative efficacy depended on baseline BCVA. At the 1-year follow-up, aflibercept exhibited some advantage over bevacizumab and ranibizumab, especially among patients with an initial baseline BCVA letter score of less than 69. However, ranibizumab and bevacizumab did not show significant differences [28, 33]. A previous meta-analysis study also confirmed that bevacizumab and ranibizumab did not differ in terms of BCVA, but ranibizumab was more effective in terms of CST reduction with a low-certainty of evidence [43]. To reinforce the validity of our meta-analysis, clinical trials comparing the 3 anti-VEGF agents with the DEX implant as well as extended follow-up trials should be conducted in the future.

Conclusions

In summary, this meta-analysis of data from four randomized clinical trials revealed that despite some ocular adverse events, DEX-treated eyes had relatively superior anatomic outcomes compared with anti-VEGF, and showed similar rates of vision improvement, while requiring fewer injections, especially in pseudophakic patients. However, considering for the restrictions of indications, the DEX implant may not be recommended as a first-line therapy for DME. In the future, randomization of these treatments would allow a definite conclusion about whether switching to a DEX implant is more beneficial rather than anti-VEGF treatment. Additionally, new treatments (monotherapy or combined therapy) should be investigated to optimize clinical efficacy and reduce side-effects.

Additional files

Additional file 1: PRISMA 2009 checklist. (PDF 316 kb)

Additional file 2: Table S1. Search strategy on PubMed; Table S2. GRADE of the evidence. (PDF 355 kb)

Abbreviations

BCVA: Best corrected visual acuity; CI: Confidence interval; CMT: Central macular thickness; CST: Central subfield thickness; DEX implant: Dexamethasone intravitreal implant; DRCR. Net: Diabetic Retinopathy Clinical Research Network; ETDRS: Early Treatment Diabetic Retinopathy Study; FDA: Food & Drug Administration; IVB: Intravitreal bevacizumab; IVR: Intravitreal ranibizumab; MD: Mean difference; ME: Macular edema; NA: Not available; OCT: Optical coherence tomography; PRN: Pro re nata; RCTs: Randomized controlled trials; RevMan: Review Manager; RR: Risk ratio; SAEs: Serious adverse events; SD: Standard deviation; SE: Standard error; VEGF: Vascular endothelial growth factor

Acknowledgements

The authors thank Ming-jie Kuang for helping with the statistical analysis.

Availability of data and materials

All data are fully available without restriction.

Authors' contributions

YH designed this study. BJH and YH collected and analyzed the data and generated the figures. WCL reviewed and revised the manuscript. XRL, XJR and BJH involved with the manuscript development, proofreading and approved the final version of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Retina, Tianjin Medical University Eye Hospital, 251 Fukang Road, Tianjin 300384, China. ²Department of Ophthalmology, The University of Hong Kong, Hong Kong, China.

Received: 26 November 2017 Accepted: 27 April 2018

Published online: 21 May 2018

References

- Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. *Surv Ophthalmol.* 1984;28 Suppl:452–61.
- Patz A, Schatz H, Berkow JW, Gittelsohn AM, Ticho U. Macular edema—an overlooked complication of diabetic retinopathy. *Trans Am Acad Ophthalmol Otolaryngol.* 1973;77:Op34–42.
- Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care.* 2012;35:556–64.
- Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. *Ophthalmology.* 1984;91:1464–74.
- Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. *Eye (Lond).* 2004;18:963–83.
- Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. *Diabetes Care.* 2010;33:2399–405.
- Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. *Ophthalmology.* 2013;120:2013–22.
- Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. *Ophthalmology.* 2012;119:789–801.

9. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatf E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. *Ophthalmology*. 2010;117:2146–51.
10. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. *Arch Ophthalmol*. 2012;130:972–9.
11. Sim DA, Keane PA, Tufail A, Egan CA, Aiello LP, Silva PS. Automated retinal image analysis for diabetic retinopathy in telemedicine. *Curr Diab Rep*. 2015;15:14.
12. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Wely D. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. *Invest Ophthalmol Vis Sci*. 2011;52:80–6.
13. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MSG. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology*. 2014;121:1904–14.
14. Sharma A, Madhusudhan RJ, Nadahalli V, Damgude SA, Sundaramoorthy SK. Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: a case report. *Indian J Ophthalmol*. 2012;60:234–5.
15. Garweg JG, Zandi S. Longterm treatment of diabetic macular edema with dexamethasone Im plant after unsatisfactory response to anti- VEGF therapy. *Investig Ophthalmol Vis Sci*. 2015;56:217.
16. Giral J, Alforja S, Keller J, Latasiewicz M, Fontecilla C, Civera AA. Intravitreal dexamethasone implant in eyes with chronic refractory diabetic macular oedema. *Investig Ophthalmol Vis Sci*. 2014;55:1782.
17. Sun HJ, Lee SJ. Reduced efficacy of intravitreal dexamethasone implant in diabetic macular edema with subfoveal cystoid spaces. *Investig Ophthalmol Vis Sci*. 2016;57:3249.
18. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM, Ozurdex CSG. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. *Retina*. 2011;31:915–23.
19. Augustin AJ, Kuppermann BD, Lanzetta P, Loewenstein A, Li X-Y, Cui H, Hashad Y, Whitcup SM. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. *BMC Ophthalmol*. 2015;15. PMID: 26519345. <https://doi.org/10.1186/s12886-015-0148-2>.
20. Cui QN, Stewart JM. Intravitreal dexamethasone implant (Ozurdex) as primary treatment for diabetic macular edema. *Investig Ophthalmol Vis Sci*. 2014;55:1780.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6:e1000097.
22. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, et al. Grading quality of evidence and strength of recommendations. *BMJ*. 2004;328:1490.
23. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, Goodwin S, Aroney C, McAllister IL, Fraser-Bell S. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. *Ophthalmology*. 2014;121:2473–81.
24. Shah SU, Harless A, Bleau L, Maturi RK. Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema. *Retina*. 2016;36:1986–96.
25. Aroney C, Fraser-Bell S, Lamoureux EL, Gillies MC, Lim LL, Fenwick EK. Vision-related quality of life outcomes in the BEVORDEX study: a clinical trial comparing Ozurdex sustained release dexamethasone intravitreal implant and bevacizumab treatment for diabetic macular edema. *Invest Ophthalmol Vis Sci*. 2016;57:5541–6.
26. Gallemore RP. Ozurdex for treatment of recalcitrant diabetic macular edema. 2017. May 31, 2017 edition: ClinicalTrials.gov.
27. Allergan: Safety and efficacy study of dexamethasone versus ranibizumab in patients with diabetic macular edema. 2015. January 29, 2015 edition: ClinicalTrials.gov.
28. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. *Ophthalmology*. 2016;123:1351–9.
29. Tang J, Kern TS. Inflammation in diabetic retinopathy. *Prog Retin Eye Res*. 2011;30:343–58.
30. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. *Semin Immunopathol*. 2008;30:65–84.
31. Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. *Retina*. 2012;32:2150–7.
32. Ciulla TA, Walker JD, Fong DS, Criswell MH. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. *Curr Opin Ophthalmol*. 2004;15:211–20.
33. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med*. 2015;372:1193–203.
34. Lam WC, Albani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA, Oliver A, Rabinovitch T, Sheidow TG, Tourville E, et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. *Clin Ophthalmol*. 2015;9:1255–68.
35. Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. *Retina*. 2015;35:1604–14.
36. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. *Cochrane Database Syst Rev* 2014;Cd007419. PMID:25342124. <https://doi.org/10.1002/14651858.CD007419.pub4>.
37. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. *JAMA Ophthalmol*. 2016;134:21–9.
38. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. *Am J Ophthalmol*. 2009;148:647–56.
39. Smiddy WE. Economic considerations of macular edema therapies. *Ophthalmology*. 2011;118:1827–33.
40. Thomas BJ, Yonekawa Y, Wolfe JD, Hassan TS. Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema. *Clin Ophthalmol*. 2016;10:1679–84.
41. Lazić R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, Tomic Z. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. *Retina*. 2014;34:719–24.
42. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). *Ophthalmologica*. 2017;237:185–222.
43. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. *Cochrane Database Syst Rev*. 2017;6:CD007419.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

